NCT03910660
A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 19 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 10, 2026 Show 11 more changesShow less
- Start date: Feb 12, 2019 to Jun 10, 2019
- Eligibility criteria expanded, about 69 words
- Primary endpoints revised (2)
- Enrollment target: 98 to 97
- Interventions: BXCL701 monotherapy (Drug), BXCL701 plus Pembrolizumab (Drug) to Pembrolizumab (Drug), Talabostat (Drug)
- Secondary endpoints: 8 to 17
- Study description shortened, about 101 words
- Site details revised at 1 of 12 sites
- Publications: details revised at 1 of 1 entry
- Study arms: 4 to 7
- Study title expanded, about 5 words
- Minor Study completion date: Dec 12, 2024 to Aug 31, 2025v20
- Minor Trial status: Active, Not Recruiting to Completed
- Primary completion date changed from estimate of Oct 2023 to Oct 31, 2023
- Study completion date changed from estimate of Dec 2025 to Dec 12, 2024
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 240 to confirmed 98
- Site details revised at 12 of 12 sites
- Notable Enrollment target: 135 to 240
- Primary completion date: Jun 2, 2022 to Oct 2023
- Study completion date: Jun 2, 2022 to Dec 2025
- Study sites revised (12)
Show 13 earlier versionsHide 13 earlier versions
- Minor Primary completion date: Apr 2, 2022 to Jun 2, 2022v16
- Notable Enrollment target: 60 to 135v15
Notable Enrollment target: 40 to 60v14 Show 7 more changesShow less
- Eligibility criteria expanded, about 7 words
- Primary endpoints: 1 to 2
- Interventions: Talabostat Mesylate plus Pembrolizumab (Drug) to BXCL701 monotherapy (Drug), BXCL701 plus Pembrolizumab (Drug)
- Secondary endpoints: 5 to 8
- Study description expanded, about 132 words
- Study title expanded, about 9 words
- Study arms: 2 to 4
- Minor Study sites: 11 to 12v12
- Notable Eligibility criteria expanded, about 64 wordsv11
Notable Eligibility criteria expanded, about 194 wordsv10 Show 5 more changesShow less
- Primary endpoint revised
- Study sites: 10 to 11
- Secondary endpoints revised (5)
- Study description expanded, about 52 words
- Study title shortened, about 4 words
- Minor Study sites: 8 to 10v9
- Notable Eligibility criteria expanded, about 60 wordsv8
- Notable Eligibility criteria expanded, about 50 words
- Study description expanded, about 15 words
- Minor Study sites: 7 to 8v6
- Minor Site contacts updated at 7 of 7 sitesv5
- Minor Study sites: 5 to 7v4
- Minor Study sites: 2 to 5v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (17)
Show 12 moreShow less
Arms and interventions
Participants will receive the combination of talabostat 0.4 mg QD orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Participants will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Participants will receive the combination of talabostat 0.3 mg twice daily (BID) (at a total daily dose \[TDD\] of 0.6 mg) orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Participants with SCNC will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Participants with adenocarcinoma will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Participants with adenocarcinoma will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Participants with adenocarcinoma will receive talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.
Drugs: Talabostat, Pembrolizumab
Sites
12 sites in 2 countries
United States 9, United Kingdom 3